These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12686341)

  • 1. Association of an activated clotting time < or =250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (a TACTICS-TIMI 18 substudy).
    Pinto DS; Lorenz DP; Murphy SA; Marble SJ; DiBattiste PM; Demopoulos LA; Cannon CP; Gibson CM;
    Am J Cardiol; 2003 Apr; 91(8):976-8, A4. PubMed ID: 12686341
    [No Abstract]   [Full Text] [Related]  

  • 2. Changes in BNP, hs-CRP and TIMI risk index with addition of tirofiban during primary percutaneous coronary intervention for acute STEMI: a prospective observational cohort study.
    Kurt IH; Demirkol S; Ünal I; Batur MK
    Anadolu Kardiyol Derg; 2012 Mar; 12(2):107-14. PubMed ID: 22281789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifibatide or tirofiban (the ACTION Trial).
    Madan M; Radhakrishnan S; Reis M; Paradiso-Hardy FL; Godin-Edgecombe M; Sparling C; Phillips AM; Shanmugasegaram S; Fort S; Naqvi SZ; Cohen EA
    Am J Cardiol; 2005 Jun; 95(11):1295-301. PubMed ID: 15904632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of reperfusion regimens with or without tirofiban in ST-elevation acute myocardial infarction.
    Martínez-Ríos MA; Rosas M; González H; Peña-Duque MA; Martínez-Sánchez C; Gaspar J; García H; Gaxiola E; Delgado L; Carrillo J; Leyva JL; Lupi E;
    Am J Cardiol; 2004 Feb; 93(3):280-7. PubMed ID: 14759375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes.
    Yip HK; Wu CJ; Chang HW; Hsieh YK; Fang CY; Chen SM; Chen MC
    Chest; 2003 Sep; 124(3):962-8. PubMed ID: 12970024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis.
    Circulation; 1997 Sep; 96(5):1445-53. PubMed ID: 9315530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and feasibility of a novel dosing regimen of tirofiban administered in patients with acute myocardial infarction with ST elevation before primary coronary angioplasty: a pilot study.
    Kochman W; Dobrzycki S; Nowak KS; Chlopicki S; Kralisz P; Prokopczuk P; Bachorzewska-Gajewska H; Gugala K; Niewada M; Mezynski G; Poniatowski B; Korecki J; Musial WJ
    J Thromb Thrombolysis; 2004 Apr; 17(2):127-31. PubMed ID: 15306748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of abciximab versus tirofiban on activated clotting time during percutaneous intervention and its relation to clinical outcomes--observations from the TARGET trial.
    Casserly IP; Topol EJ; Jia G; Lange RA; Hamm C; Meier B; DiBattiste PM; Lakkis N; Chew DP; Stone GW; Cohen DJ; Moliterno DJ
    Am J Cardiol; 2003 Jul; 92(2):125-9. PubMed ID: 12860211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.
    Kabbani SS; Aggarwal A; Terrien EF; DiBattiste PM; Sobel BE; Schneider DJ
    Am J Cardiol; 2002 Mar; 89(5):647-50. PubMed ID: 11867064
    [No Abstract]   [Full Text] [Related]  

  • 11. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
    Brener SJ; Moliterno DJ; Lincoff AM; Steinhubl SR; Wolski KE; Topol EJ
    Circulation; 2004 Aug; 110(8):994-8. PubMed ID: 15302778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
    Zhang Y; Gao C; Liu H; Wang X; Yang H; Li M; Wang X; Zhu Z; Hu D
    Clin Exp Pharmacol Physiol; 2013 Apr; 40(4):289-94. PubMed ID: 23551127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy).
    Gibson CM; Singh KP; Murphy SA; DiBattiste PM; Demopoulos LA; Cannon CP; Braunwald E;
    Am J Cardiol; 2004 Aug; 94(4):492-4. PubMed ID: 15325937
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.
    Januzzi JL; Snapinn SM; DiBattiste PM; Jang IK; Theroux P
    Circulation; 2002 May; 105(20):2361-6. PubMed ID: 12021221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the i-STAT handheld activated clotting time with the Hemochron activated clotting time during and after percutaneous coronary intervention.
    Schussler JM; Aguanno JJ; Glover EN; Vish NA; Wissinger LA; Schumacher JR; Wheelan KR
    Am J Cardiol; 2003 Feb; 91(4):464-6. PubMed ID: 12586268
    [No Abstract]   [Full Text] [Related]  

  • 16. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial.
    Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW;
    JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects on thrombin generation of the platelet glycoprotein IIb/IIIa inhibitors abciximab versus tirofiban during coronary intervention.
    Ambrose JA; Doss R; Geagea JM; Hawkey MC; Duvuri S; Giedd K; Dominguez A; Coppola J; Nguyen TH; Palla V; Barua RS; Saha DC
    Am J Cardiol; 2001 May; 87(10):1231-3: A8. PubMed ID: 11356410
    [No Abstract]   [Full Text] [Related]  

  • 19. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban.
    Schneider DJ; Herrmann HC; Lakkis N; Aguirre F; Wan Y; Aggarwal A; Kabbani SS; DiBattiste PM
    Am J Cardiol; 2002 Dec; 90(12):1421-3. PubMed ID: 12480064
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.